Alkermes Crecimiento futuro
Future controles de criterios 3/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Alkermes de 41.1% y 9.9% por año respectivamente. Se prevé que el BPA crezca en un 40.2% al año. Se espera que la rentabilidad financiera sea de 11.2% en 3 años.
Información clave
41.1%
Tasa de crecimiento de los beneficios
40.17%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.4% |
| Tasa de crecimiento de los ingresos | 9.9% |
| Rentabilidad financiera futura | 11.18% |
| Cobertura de analistas | Good |
| Última actualización | 07 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización del análisis • May 01
ALKS: Sleep And Narcolepsy Franchise Will Drive Future Upside Potential
Analysts have nudged Alkermes' fair value estimate slightly higher to about $57.33, reflecting updated assumptions for revenue growth, stronger margins and a lower future P/E that are echoed in recent price target revisions and commentary around the company's sleep and narcolepsy franchises. Analyst Commentary Recent research on Alkermes points to a mixed but generally constructive backdrop, with several bullish analysts emphasizing the potential of the sleep and narcolepsy portfolio and its impact on valuation assumptions.
Actualización del análisis • Apr 16
ALKS: Sleep Franchise And Orexin Program Will Shape Future Upside Potential
Narrative Update: Alkermes Analyst Price Target Shift The updated analyst price target for Alkermes moves modestly higher by about $0.53, as analysts factor in revised assumptions around revenue growth, profit margins, and a higher future P/E, tied in part to the evolving sleep and narcolepsy franchise following recent research updates. Analyst Commentary Recent research on Alkermes reflects a mix of optimism around the sleep and narcolepsy portfolio and caution on execution, pricing assumptions, and the performance of legacy products.Actualización del análisis • Apr 01
ALKS: Sleep Franchise And Orexin Pipeline Will Drive Future Upside
Analysts made a small upward adjustment in the price target for Alkermes to about $43.71, supported by refreshed models around the company's emerging sleep and narcolepsy franchise, recent M&A activity in the biotech space, and updated views on future P/E multiples and profitability. Analyst Commentary Recent Street research on Alkermes circles around how the emerging sleep and narcolepsy franchise, the Avadel acquisition, and updated pricing assumptions could feed into growth expectations, while also flagging execution and valuation risks.
Actualización del análisis • Mar 18
ALKS: Sleep Franchise And Orexin Breakthrough Will Drive Future Upside Potential
Narrative Update The updated analyst price target for Alkermes moves to $31.30 from $30.00, as analysts factor in revised revenue growth assumptions tied to the expanding sleep and narcolepsy franchise and the completed Avadel acquisition, along with adjusted views on profit margins and future P/E. Analyst Commentary Recent Street research on Alkermes presents a mixed picture, with analysts weighing the potential of the sleep and narcolepsy franchise against execution and valuation questions.Actualización del análisis • Mar 04
ALKS: Emerging Sleep Franchise And Orexin Program Will Drive Future Upside
Narrative Update on Alkermes The updated analyst price target for Alkermes edges down from $43.75 to about $43.65, as analysts balance slightly higher modeled revenue growth with lower profit margin assumptions and a higher future P/E tied to the growing sleep and narcolepsy franchise, including Lumryz and the orexin program. Analyst Commentary Recent Street research on Alkermes presents a mixed picture, with some analysts leaning constructive on the emerging sleep and narcolepsy portfolio and others more restrained on valuation and execution risk.Actualización del análisis • Feb 18
ALKS: Improved CVR Offer Terms Will Support Future Sleep Disorder Leadership
Analysts have slightly lowered their price target on Alkermes to $43.75 from $43.81, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E after reviewing the company's revised offer terms highlighted in recent Street research. Analyst Commentary Recent Street research around Alkermes is centered on the revised offer terms, especially the contingent value right, or CVR, structure that sits alongside the upfront consideration.Actualización del análisis • Feb 04
ALKS: Avadel Bid And Orexin Breakthrough Status Will Support Future Sleep Leadership
Analysts kept their Alkermes fair value estimate steady at about $43.81 per share while nudging up projected revenue growth and future P/E assumptions and trimming profit margin expectations, reflecting mixed reactions to the latest narcolepsy data and the evolving Avadel bid. Analyst Commentary Street research around Alkermes focuses on the mixed narcolepsy data, the competitive orexin pipeline, and the evolving Avadel bid, with investors weighing both upside optionality and execution risks.Actualización del análisis • Jan 20
ALKS: Avadel Sleep Deal And Orexin Breakthrough Designation Will Drive Upside
Analysts have trimmed their Alkermes price target by a small amount to reflect a slightly higher discount rate and somewhat lower expected profit margin, while still factoring in stronger modeled revenue growth and updated views on the Avadel acquisition and alixorexton sleep pipeline data. Analyst Commentary Bullish analysts are generally framing the recent updates around Alkermes as a mixed but constructive setup, with the Avadel acquisition and alixorexton data keeping the stock firmly on institutional radar.Seeking Alpha • Jan 09
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside
Summary Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS’s robust legacy portfolio funds rapid R&D expansion, with Lybalvi sales up 32% and strong gross-to-net dynamics supporting operational profitability. Alixorexton’s Phase 2 success in both narcolepsy types and idiopathic hypersomnia, plus a clean safety profile, significantly de-risk the clinical pipeline. The Avadel deal provides immediate revenue, a seasoned sales force, and reduces commercial launch risk for alixorexton, despite integration and financial risks. Read the full article on Seeking AlphaActualización del análisis • Jan 06
ALKS: Sleep Franchise Acquisition Will Drive Future Orexin Class Leadership
Analysts have trimmed their Alkermes fair value estimate by about $0.06 per share to $43.81 as they weigh mixed alixorexton data against generally positive views on the Avadel acquisition and Alkermes' role in the emerging orexin class. Analyst Commentary Street research around Alkermes and its sleep portfolio is split between enthusiasm for the Avadel acquisition and orexin opportunity, and caution around alixorexton data quality and competitive pressures.Actualización del análisis • Dec 20
ALKS: Avadel Deal And Sleep Franchise Are Poised To Drive Upside
The analyst price target for Alkermes has been raised by about $4 to approximately $57 per share, as analysts factor in stronger expected revenue growth and profit margins supported by the strategic Avadel acquisition and resilient alixorexton sleep-disorder franchise prospects. Analyst Commentary Bullish analysts emphasize that the Avadel transaction, combined with a clearer outlook for alixorexton in narcolepsy and hypersomnia, materially improves Alkermes' growth, margin, and capital allocation story.Actualización del análisis • Dec 06
ALKS: Sleep Medicine Acquisition Will Drive Future Orexin Opportunity Upside
Analysts modestly lift their price target on Alkermes, reflecting confidence that the strategically priced Avadel acquisition, solid narcolepsy data and an underappreciated orexin class opportunity can drive upside, despite only incremental changes to long term growth and profitability assumptions. Analyst Commentary Street views on Alkermes remain mixed, with a generally constructive stance on long term positioning in sleep medicine and orexin agonists, tempered by questions around differentiation, safety profile and competitive intensity.Actualización del análisis • Nov 21
ALKS: Sleep Medicine Acquisition Will Drive Momentum After Narcolepsy Study Results
Analysts have slightly reduced their price target for Alkermes to $43.88 from $44, reflecting tempered revenue growth assumptions and competitive data from recent narcolepsy studies. Analyst Commentary Analyst sentiment regarding Alkermes remains divided following the latest developments in its narcolepsy franchise and pending acquisition of Avadel Pharmaceuticals.Actualización del análisis • Nov 06
ALKS: Clinical Progress In Narcolepsy Will Drive Share Momentum This Fall
Analysts have raised their fair value estimate for Alkermes from $42.53 to $44.00 per share. They cite stronger revenue growth forecasts and recent clinical and strategic updates, which improve the company's near- and mid-term outlook.Artículo de análisis • Oct 31
Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next
As you might know, Alkermes plc ( NASDAQ:ALKS ) just kicked off its latest third-quarter results with some very strong...Actualización del análisis • Oct 22
Analyst Commentary Highlights Growth Prospects and Risks Following Alkermes Acquisition and Updated Valuation
Alkermes' analyst price target was raised approximately $0.95 to $42.53 per share, as analysts point to improved profit margin outlook and the anticipated benefits from its Avadel Pharmaceuticals acquisition. These factors are expected to support both near- and mid-term growth.Artículo de análisis • May 31
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Alkermes fair value estimate is US$59.40 Current share price...Seeking Alpha • Feb 25
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Summary Recently, Alkermes refocused on neuroscience, and now it’s dealing with stabilizing revenues from core products like Lybalvi, Vivitrol, Aristada, and Vumerity. However, the main growth driver going forward will be ALKS 2680. This is a once-daily oral OX2R agonist for narcolepsy treatment. ALKS is also now debt‑free with strong cash reserves and positive cash flow. So, it should be able to self fund its new bet on ALKS 2680. Their key Phase 2 trials are currently with Vibrance‑1 and Vibrance‑2, which could give us a clearer picture of ALKS 2680’s true potential. I accept ALKS trades at a slight premium relative to its peers, but it has robust financials and great cash flow to bet on ALKS 2680. So, I reiterate my “Buy” on ALKS stock. Read the full article on Seeking AlphaSeeking Alpha • Nov 24
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Summary Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a positive cash flow of $73.3 million in Q3, Alkermes can effectively fund R&D and operations. Risks include potential clinical trial failures for ALKS 2680 and competitive pressures in the CNS market, but long-term prospects remain favorable. Despite trading near fair value, ALKS's robust financials and positive cash flow support its R&D and potential future growth, making it a viable "buy on dips" stock. Read the full article on Seeking Alpha
Nuevo análisis • Aug 31
Robust Product Demand And Critical Innovations Set To Propel Growth, Amid Analysts' Concerns And Revenue Diversification Challenges
Proprietary products and strategic sales like the Athlone facility sale signal robust revenue growth and operational efficiency, showing promise for future earnings.Seeking Alpha • Jul 28
Alkermes: Fairly Valued After Post-Earnings Bump
Summary Today, we take a look at Alkermes plc, a mid-cap biopharma company headquartered in Dublin, Ireland. The company has several products on the market and the stock has moved up 15% in the past two weeks, thanks to sector rotation and solid Q2 results. Management has done a solid job in recent quarters streamlining the company, and Alkermes also has a significant stock buyback program. The shares still trade under 11 times forward earnings. Still more upside ahead? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 17
The Bottom Fishing Club: Alkermes Has Great Value And Safety
Summary Alkermes is positioned for outperformance in the pharmaceutical sector due to its conservative cash-heavy balance sheet and high-margin business model. The company focuses on therapies for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and neurological disorders like narcolepsy. Alkermes has a very low valuation compared to peers in the pharmaceutical industry, making it an interesting pick to add defensive characteristics to your portfolio. Read the full article on Seeking AlphaSeeking Alpha • Apr 09
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Summary Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 study for ALKS-2680 in Narcolepsy Type 2 later this year. Q4 earnings show robust revenue growth, led by Lybalvi, which significantly outpaced other products with 61% year-over-year growth. Financially healthy, Alkermes has a strong balance sheet, positive cash flow, and anticipates growth in revenue and net income for 2024. I am maintaining my "Buy" rating based on Q4 earnings, ALKS-2680's potential in a growing narcolepsy market, despite risks from generic competition and market sentiment. Read the full article on Seeking AlphaSeeking Alpha • Jan 26
Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet
Summary Alkermes plc, a neuroscience company, has undergone restructuring and simplification, including spinning out its oncology business and selling its manufacturing facility. Despite a turbulent year, Alkermes' stock price remains relatively stable, but the company has not recorded a net profit in recent years. Alkermes' product portfolio includes Vivitrol, Aristada, and Lybalvi, with positive revenue growth, but the company will need to diversify to offset declining sales of Vivitrol. A narcolepsy drug candidate intrigues, given its "blockbuster" revenue potential, although Avadel Pharma's recent approval for Lumryz clouds the outlook. All things considered, while Alkermes has solved some major problems in 2023, I would assign the company a "Hold" recommendation in 2024 due to a lack of compelling growth catalysts. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 2,075 | 234 | 694 | 410 | 13 |
| 12/31/2027 | 1,886 | 119 | 474 | 299 | 17 |
| 12/31/2026 | 1,811 | -65 | 352 | 41 | 17 |
| 3/31/2026 | 1,562 | 153 | 222 | 256 | N/A |
| 12/31/2025 | 1,476 | 242 | 480 | 521 | N/A |
| 9/30/2025 | 1,521 | 338 | 491 | 541 | N/A |
| 6/30/2025 | 1,505 | 348 | 480 | 521 | N/A |
| 3/31/2025 | 1,514 | 356 | 482 | 517 | N/A |
| 12/31/2024 | 1,558 | 372 | 406 | 439 | N/A |
| 9/30/2024 | 1,505 | 387 | 315 | 356 | N/A |
| 6/30/2024 | 1,508 | 386 | 327 | 374 | N/A |
| 3/31/2024 | 1,726 | 570 | 394 | 444 | N/A |
| 12/31/2023 | 1,663 | 519 | 353 | 401 | N/A |
| 9/30/2023 | 1,591 | 455 | 254 | 295 | N/A |
| 6/30/2023 | 1,462 | 300 | 159 | 196 | N/A |
| 3/31/2023 | 1,121 | -9 | -59 | -22 | N/A |
| 12/31/2022 | 1,112 | -33 | -17 | 21 | N/A |
| 9/30/2022 | 1,132 | -129 | 14 | 51 | N/A |
| 6/30/2022 | 1,173 | -94 | 102 | 133 | N/A |
| 3/31/2022 | 1,201 | -62 | 140 | 169 | N/A |
| 12/31/2021 | 1,174 | 76 | 73 | 102 | N/A |
| 9/30/2021 | 1,129 | -92 | 112 | 138 | N/A |
| 6/30/2021 | 1,100 | -63 | 88 | 115 | N/A |
| 3/31/2021 | 1,044 | -95 | 48 | 78 | N/A |
| 12/31/2020 | 1,039 | -111 | 41 | 83 | N/A |
| 9/30/2020 | 1,171 | -74 | -11 | 58 | N/A |
| 6/30/2020 | 1,162 | -126 | -53 | 28 | N/A |
| 3/31/2020 | 1,194 | -139 | -78 | 10 | N/A |
| 12/31/2019 | 1,171 | -197 | N/A | 72 | N/A |
| 9/30/2019 | 1,074 | -201 | N/A | 91 | N/A |
| 6/30/2019 | 1,067 | -183 | N/A | 93 | N/A |
| 3/31/2019 | 1,092 | -173 | N/A | 148 | N/A |
| 12/31/2018 | 1,094 | -139 | N/A | 99 | N/A |
| 9/30/2018 | 1,054 | -139 | N/A | 75 | N/A |
| 6/30/2018 | 1,023 | -141 | N/A | 61 | N/A |
| 3/31/2018 | 937 | -152 | N/A | 6 | N/A |
| 12/31/2017 | 903 | -158 | N/A | 19 | N/A |
| 9/30/2017 | 842 | -169 | N/A | -9 | N/A |
| 6/30/2017 | 804 | -196 | N/A | -14 | N/A |
| 3/31/2017 | 781 | -200 | N/A | -20 | N/A |
| 12/31/2016 | 746 | -208 | N/A | -64 | N/A |
| 9/30/2016 | 695 | -257 | N/A | -69 | N/A |
| 6/30/2016 | 668 | -275 | N/A | -113 | N/A |
| 3/31/2016 | 624 | -274 | N/A | -100 | N/A |
| 12/31/2015 | 628 | -227 | N/A | -40 | N/A |
| 9/30/2015 | 640 | -127 | N/A | -29 | N/A |
| 6/30/2015 | 648 | -86 | N/A | -7 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (41.1% al año) de ALKS es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (41.1% al año) de ALKS crezcan más rápidamente que el mercado US (16.7% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de ALKS crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (9.9% al año) de ALKS crezcan más despacio que el mercado de US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 9.9% al año) de ALKS crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de ALKS sea baja dentro de 3 años (11.2%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/11 15:07 |
| Precio de las acciones al final del día | 2026/05/11 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Alkermes plc está cubierta por 34 analistas. 17 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Luke Herrmann | Baird |